November 28, 2016 - By Vivian Park · 0 Comments
The stock of Cymabay Therapeutics Incorporated (NASDAQ:CBAY) registered a decrease of 0.5% in short interest. CBAY’s total short interest was 315,800 shares in November as published by FINRA. Its down 0.5% from 317,400 shares, reported previously. With 99,300 shares average volume, it will take short sellers 3 days to cover their CBAY’s short positions. The short interest to Cymabay Therapeutics Incorporated’s float is 1.47%. About 14,886 shares traded hands. CymaBay Therapeutics Inc (NASDAQ:CBAY) has declined 21.34% since April 25, 2016 and is downtrending. It has underperformed by 27.36% the S&P500.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $46.92 million. The Firm is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. It currently has negative earnings. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982.
Out of 3 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Cymabay Therapeutics Inc has been the topic of 5 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The company was initiated on Tuesday, July 21 by Piper Jaffray. On Friday, July 1 the stock rating was initiated by Roth Capital with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 8. H.C. Wainwright maintained CymaBay Therapeutics Inc (NASDAQ:CBAY) on Wednesday, March 30 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, June 1 by H.C. Wainwright.
CymaBay Therapeutics, Inc., incorporated on October 5, 1988, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s pipeline includes three unpartnered clinical stage product candidates and a number of preclinical programs. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). MBX-2982 is an oral, G-protein coupled receptor (GPR119) agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health.
More recent CymaBay Therapeutics Inc (NASDAQ:CBAY) news were published by: Globenewswire.com which released: “CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 …” on October 20, 2016. Also Quotes.Wsj.com published the news titled: “News CymaBay Therapeutics Inc.CBAY” on February 20, 2011. Seekingalpha.com‘s news article titled: “CymaBay Therapeutics’ (CBAY) CEO Hal Van Wart on Q2 2016 Results – Earnings …” with publication date: August 10, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park